Articles related to ANTIHYPERTENSIVES

Intensive blood-pressure lowering reduced major cardiovascular events similarly in adults with and without chronic kidney disease, without increasing kidney failure risk, although sustained declines in estimated glomerular filtration rate occurred more frequently.

Losartan increased brown-fat metabolic activity in cell and mouse experiments, while a large imaging analysis linked brown fat and ARB exposure with favorable metabolic patterns. Whether the drug can produce similar metabolic effects clinically remains unproven.

A 31,000-patient observational study found that dihydropyridine calcium-channel blockers were associated with a 33% higher risk of major adverse kidney events in type 2 diabetes patients already on RASi and SGLT2i therapy.

A network meta-analysis of 716 randomized trials and 159,362 participants found ARB-based regimens had the lowest rates of treatment discontinuation due to adverse effects, with the ARB-CCB combination ranking as the best-tolerated dual-drug option among antihypertensive regimens examined.

In two randomized phase‑3 trials, a single‑pill triple low‑dose antihypertensive combination achieved blood pressure reductions comparable to amlodipine and superior to losartan monotherapy over 8 weeks.

Baxdrostat significantly reduced seated systolic blood pressure compared to placebo in 796 patients, with placebo-adjusted reductions of 9.8 mmHg and 8.7 mmHg at the 2 mg and 1 mg doses respectively, without impacting cortisol levels.